TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
- None.
- None.
Insights
TransCode Therapeutics' collaboration with Debiopharm represents a strategic alliance aimed at enhancing the precision and efficacy of cancer treatments through advanced drug delivery systems. The integration of TransCode's TTX delivery platform with Debiopharm's drug delivery technologies could lead to significant advancements in targeted nucleic acid therapeutics. This is particularly important in the field of oncology, where the specificity of drug delivery can greatly influence therapeutic outcomes.
Targeted nucleic acid delivery is critical in the development of personalized medicine, which tailors treatment to individual patient profiles, potentially reducing side effects and improving patient outcomes. The use of TransCode's TTX platform to deliver a range of nucleic acid therapeutics, including CRISPR-based genome-editing tools, could be a game-changer in the treatment of metastatic cancers, which are notoriously difficult to treat.
Investors and stakeholders should monitor the progress of the early-stage clinical trial for TTX-MC138, as positive results could lead to increased valuation of TransCode's intellectual property and potential licensing deals. Moreover, the success of this collaboration may attract additional partnerships, enhancing the companies' competitive positions within the biopharmaceutical industry.
The co-research agreement between TransCode and Debiopharm is poised to explore the synergistic potential of combining two innovative technologies in the fight against cancer. The TTX delivery platform's ability to deliver various nucleic acid therapeutics directly to cancer cells is particularly promising for advancing cancer treatment modalities. By focusing on antigen-selective delivery, this approach may increase the precision of oncology therapeutics, potentially leading to treatments with fewer off-target effects and better patient tolerability.
Antisense oligonucleotides, one of the therapeutic modalities mentioned, are single-stranded DNA molecules designed to interfere with the expression of specific genes. By silencing genes that are overexpressed in cancer cells, these oligonucleotides can inhibit tumor growth and metastasis. The early-stage clinical trial of TTX-MC138 will be an important indicator of the efficacy of this technology in a clinical setting.
Furthermore, the use of CRISPR technology within the TTX platform may offer a novel approach to cancer treatment by enabling precise gene editing within tumor cells. This could potentially result in curative therapies for certain types of cancer. The success of these preclinical studies will be crucial for advancing these therapies to clinical trials and ultimately to market, where they could provide new options for patients with limited treatment alternatives.
The strategic partnership between TransCode Therapeutics and Debiopharm is indicative of a broader trend in the pharmaceutical industry towards collaboration in research and development to expedite the discovery and commercialization of new therapies. This collaboration leverages the complementary strengths of both companies, potentially reducing the time and cost associated with bringing new cancer treatments to market.
From a market perspective, the successful development of targeted nucleic acid therapeutics could capture a significant share of the burgeoning personalized medicine market. As cancer remains one of the leading causes of death globally, there is a substantial market demand for innovative and effective treatments. The ability to deliver mRNA and other nucleic acids directly to cancer cells could position TransCode and Debiopharm as leaders in the next wave of oncology therapeutics.
Investors should consider the implications of this collaboration on the companies' long-term growth potential. A successful partnership could lead to increased investor confidence and a positive impact on stock performance. However, the inherent risks of drug development, including the possibility of unsuccessful clinical trials or regulatory hurdles, should be carefully weighed.
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics. TransCode has developed and tested the TTX platform for the delivery of various nucleic acid therapeutics to cancer cells, including small interfering RNAs, antisense oligonucleotides, immunostimulatory oligonucleotides, mRNA, and genome-editing ribonucleoprotein complexes (CRISPR). TransCode’s lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial. As part of the collaboration, TransCode will combine its TTX delivery platform with Debiopharm’s proprietary technologies to generate constructs designed to provide targeted mRNA delivery to cancer cells. Under the agreement, these constructs will be tested both in cancer cells and in tumor-bearing animals.
Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities. Debiopharm’s ongoing quest towards developing highly innovative drug delivery methods is based on the recognition that novel targeted medicines hold the potential to revolutionize cancer research and treatment by improving precision, efficacy, safety, and the overall therapeutic outcome for cancer patients. The company hopes that future advancements could usher in a new era of more effective and personalized cancer therapies.
Frédéric Lévy, Debiopharm’s Chief Scientific Officer, commented, “We believe that TransCode’s TTX platform has the potential to bring about significant advances in drug delivery for cancer because of its versatility in terms of the payloads it can be used to deliver, including not only a wide array of nucleic acids but also peptides and proteins.”
Zdravka Medarova, TransCode’s Chief Scientific Officer, added, “Debiopharm is a global player in the field of cancer therapeutics, known for the development of standard of care drugs for the treatment of various types of cancer. For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”
Financial terms were not disclosed.
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
For more information, please visit www.transcodetherapeutics.com.
About Debiopharm
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, Debiopharm identifies high-potential compounds and technologies for in licensing, clinically tests their safety and efficacy, and then selects large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com and follow Debiopharm on Twitter at http://twitter.com/DebiopharmNews.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the therapeutic potential of TransCode’s development candidates and its TTX delivery platform generally, either on a stand-alone basis or in combination with the development candidates and technologies of third parties, and statements concerning TransCode’s collaboration agreement with Debiopharm. No assurance can be provided as to the ultimate success of any collaboration agreement, including the collaboration agreement with Debiopharm. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risks that results of our clinical trials will not be consistent with our pre-clinical studies or expectations or with preceding clinical trials; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s conduct of clinical trials; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.
For more information, please contact:
TransCode Therapeutics, Inc.
Tom Fitzgerald, Interim CEO; CFO
tom.fitzgerald@transcodetherapeutics.com
FAQ
What is the co-research agreement announced by TransCode Therapeutics, Inc. (NASDAQ: RNAZ)?
What is the lead therapeutic candidate being evaluated in an early-stage clinical trial by TransCode Therapeutics, Inc. (NASDAQ: RNAZ)?
What is the aim of the collaboration between TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Debiopharm?
Who is Debiopharm's Chief Scientific Officer and what did they comment on?
